Unicycive Therapeutics, Inc.

NasdaqCM:UNCY Stock Report

Market Cap: US$61.3m

Unicycive Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Unicycive Therapeutics has a total shareholder equity of $27.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $38.6M and $10.7M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$32.35m
EquityUS$27.85m
Total liabilitiesUS$10.72m
Total assetsUS$38.57m

Recent financial health updates

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 21
We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

Feb 16
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 18
We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Recent updates

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 21
We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

Feb 16
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 18
We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely

Mar 08
Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely

Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

Sep 07

Unicycive Therapeutics GAAP EPS of -$0.24

Aug 16

Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

Jul 18

Financial Position Analysis

Short Term Liabilities: UNCY's short term assets ($37.7M) exceed its short term liabilities ($10.5M).

Long Term Liabilities: UNCY's short term assets ($37.7M) exceed its long term liabilities ($265.0K).


Debt to Equity History and Analysis

Debt Level: UNCY is debt free.

Reducing Debt: UNCY currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UNCY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if UNCY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies